BioPorto A/S

Copenhagen Stock Exchange BIOPOR.CO

BioPorto A/S Operating Cash Flow for the year ending December 31, 2023: USD -8.21 M

BioPorto A/S Operating Cash Flow is USD -8.21 M for the year ending December 31, 2023, a -8.99% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

BioPorto A/S Operating Cash Flow for the year ending December 31, 2022 was USD -7.53 M, a 23.69% change year over year.
BioPorto A/S Operating Cash Flow for the year ending December 31, 2021 was USD -9.87 M, a -69.18% change year over year.
BioPorto A/S Operating Cash Flow for the year ending December 31, 2020 was USD -5.83 M, a 35.23% change year over year.
BioPorto A/S Operating Cash Flow for the year ending December 31, 2019 was USD -9.01 M, a -54.27% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Copenhagen Stock Exchange: BIOPOR.CO

BioPorto A/S

CEO	Mr. Peter Moerch Eriksen B.B.A., BBA
IPO Date	Jan. 13, 2000
Location	Denmark
Headquarters	Tuborg Havnevej 15, st.
Employees	27
Sector	Healthcare
Industries Biotechnology 3D Printing Chemicals & Advanced Materials Cleaning Supplies Composite Materials Medical Instruments Personal Care Plastics

Description

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.

Key trends

Past 5 years